Valuation : Laboratorios Farmaceuticos Rovi, S.A.

Market Cap 2.93B 3.4B 2.78B 2.52B 4.72B 325B 4.75B 32.98B 12.68B 165B 12.78B 12.5B 523B P/E 2026 *
20.5x
P/E 2027 * 16.9x
Enterprise Value 2.92B 3.39B 2.76B 2.5B 4.7B 323B 4.72B 32.8B 12.61B 165B 12.71B 12.44B 520B EV / Sales 2026 *
3.78x
EV / Sales 2027 * 3.2x
Free-Float
31.63%
Yield 2026 *
1.71%
Yield 2027 * 2.04%
1 day+1.98%
3 months+1.98%
6 months+1.98%
Current year+1.98%
Current year 67.17
Extreme 67.17
67.17
1 year 67.17
Extreme 67.17
67.17
3 years 52
Extreme 52
90.61
5 years 0.03
Extreme 0.03
90.61
10 years 0.03
Extreme 0.03
90.61
Manager TitleAgeSince
Chief Executive Officer - 27/07/2007
Director of Finance/CFO - 01/01/2001
Chief Operating Officer - -
Director TitleAgeSince
Chairman - 17/07/2021
Director/Board Member - 27/07/2007
Director/Board Member - 27/07/2007
Change 5-day change 1-year change 3-year change Capi.($)
+1.98%-.--% - - 3.4B
-0.65%-2.93%+47.70%+86.17% 994B
-0.29%-3.51%+49.15%+62.35% 640B
+0.83%+0.26%+17.76%+72.25% 454B
-0.38%-3.59%+30.13%+35.17% 337B
-0.09%-13.54%+13.34%+24.95% 261B
-0.43%-2.48%-0.73%+9.58% 246B
-1.34%-13.70%+36.53%+44.96% 204B
-3.44%-7.51%-20.63%-59.44% 190B
-0.75%-4.82%+25.46%+87.14% 178B
Average -0.46%-5.76%+22.08%+40.35% 389.42B
Weighted average by Cap. -0.50%-4.42%+30.96%+54.95%

Financials

2026 *2027 *
Net sales 772M 896M 731M 662M 1.24B 85.57B 1.25B 8.68B 3.34B 43.53B 3.36B 3.29B 138B 891M 1.03B 843M 765M 1.43B 98.77B 1.44B 10.02B 3.85B 50.25B 3.88B 3.8B 159B
Net income 129M 149M 122M 110M 207M 14.25B 208M 1.45B 556M 7.25B 560M 548M 22.91B 174M 202M 165M 149M 280M 19.28B 281M 1.96B 752M 9.81B 758M 741M 31B
Net Debt -16.21M -18.82M -15.35M -13.92M -26.11M -1.8B -26.24M -182M -70.12M -915M -70.67M -69.12M -2.89B -81.51M -94.6M -77.18M -69.95M -131M -9.04B -132M -917M -352M -4.6B -355M -347M -14.53B
Logo Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - prescription pharmaceuticals (49%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - pharmaceutical products manufactured under contract (44%); - diagnostic products (7%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (95.4%) and sales of services (4.6%). Net sales are distributed geographically as follows: Spain (77%), Italy (5%), Germany (3%), Portugal (2%), France (1%), Greece (1%) and other (11%).
Employees
2,470
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
57.35EUR
Average target price
74.36EUR
Spread / Average Target
+29.65%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!